Nephrology Times最新文献_第8页

Alemtuzumab Rivals Conventional Induction Agents in Multicenter Trial 阿仑单抗在多中心试验中与传统诱导药物竞争

Nephrology Times Pub Date : 2011-06-01 DOI: 10.1097/01.NEP.0000399780.93032.10

F. Lowry

引用次数: 0

The Long and Short of Posttransplant Care 移植后护理的长与短

Nephrology Times Pub Date : 2011-06-01 DOI: 10.1097/01.NEP.0000399781.70161.DD

T. Bunchman

引用次数: 0

BK Virus Allograft Nephropathy: Unresolved Issues Complicate Diagnosis and Management BK病毒异体移植肾病:未解决的问题使诊断和管理复杂化

Nephrology Times Pub Date : 2011-06-01 DOI: 10.1097/01.NEP.0000399784.15904.40

G. Gupta, M. Atta

{"title":"BK Virus Allograft Nephropathy: Unresolved Issues Complicate Diagnosis and Management","authors":"G. Gupta, M. Atta","doi":"10.1097/01.NEP.0000399784.15904.40","DOIUrl":"https://doi.org/10.1097/01.NEP.0000399784.15904.40","url":null,"abstract":"BK virus has emerged as an important cause of graft loss in kidney transplant recipients. While surveillance strategies have increased early detection and, consequently, reduced graft loss, achieving a delicate balance in the use of potent immunosuppression remains key to preventing acute rejection and BK virus reactivation. In the kidney transplant population, BK virus, a polyomavirus, fi rst emerged as a clinical concern only in the mid1990s, after the introduction of more potent immunosuppressive medications. A signifi cant correlation was observed between the emergence of the infection and of the immunosuppressive regimen containing lymphocytedepleting agents for induction therapy followed by maintenance with calcineurin inhibitors (CNIs) and antiproliferative agents (mycophenolate mofetil, or MMF). At the current time, though, it seems more likely that the risk of BK virus reactivation relates to the total burden of immunosuppression, not to any one drug. Although the majority of reactivation occurs in the fi rst year posttransplant, BK virus nephropathy is a well-known cause of late allograft dysfunction. Risk factors for the condition include male gender, history of acute rejection, prolonged cold ischemia time, and degree of HLA mismatch. A robust association has been demonstrated between BK virus nephropathy and recipient seronegativity at the time of transplantation, similar to the epidemiology of other opportunistic viruses— e.g., herpes viruses, Epstein-Barr virus, and cytomegalovirus. Despite this known risk, testing for BK virus serostatus is not routinely performed, probably because seropositive renal transplant recipients can also develop BK virus nephropathy. Thus, although the precise etiopathogenesis remains unclear, BK virus nephropathy likely arises from complementary determinants in the host, the allograft, and the virus, in the setting of immunosuppression. When BK virus nephropathy does occur, reported rates of graft loss have ranged from 10% to 80%.","PeriodicalId":380758,"journal":{"name":"Nephrology Times","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2011-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116008133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tolerance Protocol Safe and Effective in HLA-Matched Kidney Transplant Recipients hla匹配肾移植受者耐受方案安全有效

Nephrology Times Pub Date : 2011-06-01 DOI: 10.1097/01.NEP.0000399782.77785.20

M. Hogan

引用次数: 0

B Cell-Targeted Therapy in Membranous Nephropathy: Time for a Randomized Trial 膜性肾病的B细胞靶向治疗:随机试验的时间

Nephrology Times Pub Date : 2011-05-01 DOI: 10.1097/01.NEP.0000398887.83065.5B

F. Fervenza

{"title":"B Cell-Targeted Therapy in Membranous Nephropathy: Time for a Randomized Trial","authors":"F. Fervenza","doi":"10.1097/01.NEP.0000398887.83065.5B","DOIUrl":"https://doi.org/10.1097/01.NEP.0000398887.83065.5B","url":null,"abstract":"Membranous nephropathy is a common immune-mediated glomerular disease and remains the leading cause of nephrotic syndrome in Caucasian adults.1 Although the disease progresses relatively slowly in most patients, approximately 40% eventually develop end-stage renal disease (ESRD).2 Despite this risk, there has been little progress in the treatment of this condition over the last 30 years. While available immunosuppressive therapies, including corticosteroids, alkylating agents, and calcineurin inhibitors, are at least partially successful in reducing proteinuria in membranous nephropathy, their use is controversial, and they all are associated with signifi cant adverse effects and a high relapse rate.3 This set of circumstances holds particularly true in the case of cyclophosphamide, where side effects include risk of infertility and the long-term increased chance of malignancy. Since membranous nephropathy is a disease with remissions and relapses, repeated use of cyclophosphamide results in a progressive increase in long-term risks. There is a need to evaluate new treatments for patients with membranous nephropathy that result in a higher response rate, lower relapse rate, and fewer adverse effects.","PeriodicalId":380758,"journal":{"name":"Nephrology Times","volume":"51 3","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2011-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"113959954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transplantation of HIV-Infected Organs: The Time Has Come 感染hiv的器官移植:时机已到

Nephrology Times Pub Date : 2011-05-01 DOI: 10.1097/01.NEP.0000398884.81279.E2

D. Segev

引用次数: 0

Belatacept: Positive Outcomes Persist Over Time, and Safety Profile Improves belataccept:随着时间的推移，积极的结果持续存在，安全性得到改善

Nephrology Times Pub Date : 2011-05-01 DOI: 10.1097/01.NEP.0000398882.73656.A7

M. Hogan

引用次数: 0

Steroid Minimization in Kidney Transplantation: Longer Follow-Up Needed 肾移植中类固醇最小化:需要更长时间的随访

Nephrology Times Pub Date : 2011-04-01 DOI: 10.1097/01.NEP.0000398061.58169.EB

M. Kamgar, S. Bunnapradist

引用次数: 1

Appropriate Funding Needed to Keep ESRD Bundle Afloat 需要适当的资金来维持ESRD的运作

Nephrology Times Pub Date : 2011-04-01 DOI: 10.1097/01.NEP.0000398059.73416.14

M. Hogan

引用次数: 0

Obesity and Kidney Disease: A Call to Action 肥胖和肾脏疾病:行动呼吁

Nephrology Times Pub Date : 2011-04-01 DOI: 10.1097/01.NEP.0000398060.50545.AA

A. Salama

引用次数: 1